MAPC/EPC Tissue-engineered Venous Valves

It is a promising method to construct tissue-engineered venous valves to treat chronic venous insufficiency. We developed a new, tissue-engineered venous valves. Advantages of such tissue-engineered venous valves could include reduced thrombogenicity and greater long-term durability. Using multipotent adult progenitor cells (MAPC) and endothelial progenitor cells(EPC) derived from bone marrow as seeding cells, and decallularised allogeneic venous valves as the scaffolds. Seeded MAPC into the walls of scaffolds, and EPC onto the surface. We called the complex of cells/scaffold—"MAPC/EPC tissue-engineered venous valves", and observed the morphous and structures. Tissue-engineered venous valves were replanted into the acceptor dog's external jugular vein with end-to-end anastomosis. The physiological dispositions of the tissue-engineered venous valves were observed. This paper included 5 sections: Characterization and differentiation of bone marrow-derived multipotent adult progenitor cells; characterization and differentiation of endothelial progenitor cells from canine bone marrow; fabrication of decellularized scaffold of venous valves; construction of tissue engineered venous valves with MAPC and EPC in vitro; investigation of tissue engineered venous valves in vivo.